Brokers Offer Predictions for VRTX FY2025 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Vertex Pharmaceuticals in a research note issued on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer expects that the pharmaceutical company will post earnings per share of $16.12 for the year. Cantor Fitzgerald has a “Overweight” rating and a $480.00 price target on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.58 per share.

VRTX has been the topic of a number of other reports. Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and lifted their price objective for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. StockNews.com downgraded Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Scotiabank lifted their target price on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 11th. Finally, Truist Financial lifted their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $505.61.

Vertex Pharmaceuticals Trading Up 0.8 %

Vertex Pharmaceuticals stock opened at $484.24 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The business’s 50-day simple moving average is $436.05 and its 200-day simple moving average is $460.70. The firm has a market capitalization of $124.35 billion, a PE ratio of -220.11, a PEG ratio of 2.07 and a beta of 0.41. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ABC Arbitrage SA bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $1,510,000. Czech National Bank raised its holdings in shares of Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock valued at $22,486,000 after purchasing an additional 3,260 shares during the period. Highview Capital Management LLC DE raised its holdings in Vertex Pharmaceuticals by 1.8% in the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company’s stock valued at $2,324,000 after acquiring an additional 102 shares during the period. Whalen Wealth Management Inc. bought a new position in Vertex Pharmaceuticals in the 3rd quarter valued at about $662,000. Finally, Davidson Investment Advisors raised its holdings in Vertex Pharmaceuticals by 26.0% in the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company’s stock valued at $24,630,000 after acquiring an additional 12,631 shares during the period. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the completion of the transaction, the executive vice president now directly owns 64,021 shares of the company’s stock, valued at approximately $29,438,776.43. This represents a 0.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.